Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical sector. He led several investments and currently represents Gilde on the boards of Lava Therapeutics B.V. and Amphista Therapeutics Ltd.
Prior to joining Gilde, Stefan worked at Merck KGaA where he completed international assignments in the Global Business Intelligence and M Ventures divisions. Additionally, he was involved in various consulting projects spanning the pharmaceutical and chemical departments at Merck and co-moderated Merck Serono’s innovation competitions.
Stefan received a B.Sc. in Biology and M.Sc. in Biotechnology from the Swiss Federal Institute of Technology Zurich (ETH) and his MPhil in Bioscience Enterprise from the University of Cambridge. He completed his Ph.D. with Nobel Laureate Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge, where he developed a bicyclic peptide-based drug discovery platform.
He is a Swiss citizen based in Gilde’s Utrecht office.
